Biotech Values

[DewDiligence]

ANDS addendum: I thought it was sneaky of the company to withhold from today’s PR that patients in the 400mg arm will not be treated until patients in the 200mg arm have been evaluated for rash and other AE’s. They did mention this design feature on today’s CC—but only because someone asked about it.

I suppose investors could have ascertained the delayed start of the 400mg arm by reading between the lines in the PR:

Anadys expects to receive 28-day safety and response (RVR) data from the 200 mg dose level by year-end and additional on-treatment safety and response data from both cohorts during the first two quarters of 2010.

Since the duration of treatment in the two arms is the same, the only possible reason for the 200mg results to be available sooner in a randomized trial such as this one is that the start of dosing in the 400mg arm is being delayed. Still, investors should not have to work this hard to obtain such an important piece of information and ANDS deserves low marks on transparency.